Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
Abstract Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long‐term surviv...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-08-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13532 |
| _version_ | 1818179577908822016 |
|---|---|
| author | Tomomi Masuda Noriaki Sunaga Norimitsu Kasahara Kazutaka Takehara Masakiyo Yatomi Kenichiro Hara Yasuhiko Koga Toshitaka Maeno Takeshi Hisada |
| author_facet | Tomomi Masuda Noriaki Sunaga Norimitsu Kasahara Kazutaka Takehara Masakiyo Yatomi Kenichiro Hara Yasuhiko Koga Toshitaka Maeno Takeshi Hisada |
| author_sort | Tomomi Masuda |
| collection | DOAJ |
| description | Abstract Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long‐term survival case of NSCLC harboring concomitant EGFR G719C and S768I mutations who received afatinib rechallenge followed by chemotherapy. The present case suggests that combined therapeutic strategies such as afatinib plus sequential chemotherapy would be beneficial based on appropriately timed rebiopsies from recurrent lesions. Key points Significant findings of the study and what this study adds A NSCLC patient carrying EGFR G719X/S768I mutations survived for a long period of time with afatinib rechallenge followed by chemotherapy. Combined therapeutic strategies should be considered based on rebiopsies in appropriate timing in NSCLC with uncommon EGFR mutations. |
| first_indexed | 2024-12-11T21:06:06Z |
| format | Article |
| id | doaj.art-fea87d23bdc74d7a9fb4cabab1c05093 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-11T21:06:06Z |
| publishDate | 2020-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-fea87d23bdc74d7a9fb4cabab1c050932022-12-22T00:50:51ZengWileyThoracic Cancer1759-77061759-77142020-08-011182351235610.1111/1759-7714.13532Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutationsTomomi Masuda0Noriaki Sunaga1Norimitsu Kasahara2Kazutaka Takehara3Masakiyo Yatomi4Kenichiro Hara5Yasuhiko Koga6Toshitaka Maeno7Takeshi Hisada8Department of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanInnovative Medical Research Center Gunma University Hospital Maebashi JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi JapanGunma University Graduate School of Health Sciences Maebashi JapanAbstract Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long‐term survival case of NSCLC harboring concomitant EGFR G719C and S768I mutations who received afatinib rechallenge followed by chemotherapy. The present case suggests that combined therapeutic strategies such as afatinib plus sequential chemotherapy would be beneficial based on appropriately timed rebiopsies from recurrent lesions. Key points Significant findings of the study and what this study adds A NSCLC patient carrying EGFR G719X/S768I mutations survived for a long period of time with afatinib rechallenge followed by chemotherapy. Combined therapeutic strategies should be considered based on rebiopsies in appropriate timing in NSCLC with uncommon EGFR mutations.https://doi.org/10.1111/1759-7714.13532Afatinibnon‐small cell lung cancerrechallengeuncommon EGFR mutation |
| spellingShingle | Tomomi Masuda Noriaki Sunaga Norimitsu Kasahara Kazutaka Takehara Masakiyo Yatomi Kenichiro Hara Yasuhiko Koga Toshitaka Maeno Takeshi Hisada Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations Thoracic Cancer Afatinib non‐small cell lung cancer rechallenge uncommon EGFR mutation |
| title | Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations |
| title_full | Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations |
| title_fullStr | Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations |
| title_full_unstemmed | Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations |
| title_short | Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations |
| title_sort | successful afatinib rechallenge in a patient with non small cell lung cancer harboring egfr g719c and s768i mutations |
| topic | Afatinib non‐small cell lung cancer rechallenge uncommon EGFR mutation |
| url | https://doi.org/10.1111/1759-7714.13532 |
| work_keys_str_mv | AT tomomimasuda successfulafatinibrechallengeinapatientwithnonsmallcelllungcancerharboringegfrg719cands768imutations AT noriakisunaga successfulafatinibrechallengeinapatientwithnonsmallcelllungcancerharboringegfrg719cands768imutations AT norimitsukasahara successfulafatinibrechallengeinapatientwithnonsmallcelllungcancerharboringegfrg719cands768imutations AT kazutakatakehara successfulafatinibrechallengeinapatientwithnonsmallcelllungcancerharboringegfrg719cands768imutations AT masakiyoyatomi successfulafatinibrechallengeinapatientwithnonsmallcelllungcancerharboringegfrg719cands768imutations AT kenichirohara successfulafatinibrechallengeinapatientwithnonsmallcelllungcancerharboringegfrg719cands768imutations AT yasuhikokoga successfulafatinibrechallengeinapatientwithnonsmallcelllungcancerharboringegfrg719cands768imutations AT toshitakamaeno successfulafatinibrechallengeinapatientwithnonsmallcelllungcancerharboringegfrg719cands768imutations AT takeshihisada successfulafatinibrechallengeinapatientwithnonsmallcelllungcancerharboringegfrg719cands768imutations |